Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT06468670
PHASE2
Short-course Radiotherapy Combined With Sintilimab for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma
Sponsor: Fujian Cancer Hospital
View on ClinicalTrials.gov
Summary
This study is aimed to evaluate the efficacy and safety of short-course radiotherapy combined with sintilimab in neoadjuvant treatment of stage III, locally advanced esophageal squamous cell carcinoma.
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2024-06-17
Completion Date
2027-06
Last Updated
2024-06-21
Healthy Volunteers
No
Conditions
Interventions
DRUG
sintilimab,programmed death 1 monoclonal antibody
short-course radiotherapy +sintilimab (200mg, iv, D1, Q3W)